ClinicalTrials.gg
CompletedNCT06272487KARDIA-3Updated Mar 2, 2026

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

A Phase 2 interventional study of Zilebesiran and Placebo in High Cardiovascular Risk and Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 195 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
420th of 1,779
375 · median 100
Started
2024
with 92 others
Phase 2
170 of 2,031
21 open now
Registered
1,762nd of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 420th largest by enrollment of the 1,779 interventional ones that give a count, is one of 93 that started in 2024, is one of 170 in phase 2, and was the 1,762nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

03

Conditions studied

  • High Cardiovascular Risk
  • Hypertension

Keywords

  • High blood pressure
  • Hypertension
  • siRNA
  • Angiotensinogen
  • AGT
  • Cardiovascular disease
  • Chronic kidney disease
  • Uncontrolled hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of cardiovascular (CV) disease, high CV risk, or estimated (eGFR) ≥30 to \<60 mL/min/1.73m\^2
  • Mean seated office SBP ≥140 mmHg and ≤170 mmHg
  • 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
  • Must be on stable therapy with 2 to 4 classes of antihypertensive medications

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension
  • Orthostatic hypotension
  • Proteinuria >3 g/day
  • Serum potassium >4.8 milliequivalents per liter (mEq/L)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    Zilebesiran

    Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.

    Drug: Zilebesiran

  • Placebo comparator
    Placebo

    Participants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.

    Drug: Placebo

Interventions

  • Zilebesiran administered by subcutaneous (SC) injection

    Also known as: ALN-AGT01

  • DrugPlacebo

    Placebo administered by SC injection

06

What researchers measure

Primary outcomes

  1. Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP)

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change from Baseline at Month 3 in 24-Hour Mean SBP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)

    Time frame: Baseline and Month 3

  2. Change from Baseline at Month 6 in Mean Seated Office SBP

    Time frame: Baseline and Month 6

  3. Change from Baseline at Month 6 in 24-Hour Mean SBP Assessed by ABPM

    Time frame: Baseline and Month 6

  4. Proportion of Patients with Mean Seated Office SBP <140 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6

    Time frame: Month 6

  5. Proportion of Patients with 24-hour Mean SBP assessed by ABPM <130 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6

    Time frame: Month 6

  6. Change from Baseline at Month 3 and Month 6 in Daytime and Nighttime Mean SBP and Diastolic Blood Pressure (DBP) assessed by ABPM

    Time frame: Baseline and Months 3 and 6

  7. Change from Baseline at Month 3 and Month 6 in Mean Seated Office DBP

    Time frame: Baseline and Months 3 and 6

  8. Change from Baseline at Month 3 and Month 6 in 24-hour Mean DBP Assessed by ABPM

    Time frame: Baseline and Months 3 and 6

  9. Change from Baseline Over Time in Serum Angiotensinogen (AGT)

    Time frame: Baseline through Month 6

07

Study locations

195 sites
  • Clinical Trial Site
    Alexander City, Alabama 35010, United States
  • Clinical Trial Site
    Daphne, Alabama 36526, United States
  • Clinical Trial Site
    Foley, Alabama 36535, United States
  • Clinical Trial Site
    Huntsville, Alabama 35801, United States
  • Clinical Trial Site
    Huntsville, Alabama 35805, United States
  • Clinical Trial Site
    Montgomery, Alabama 36117, United States
  • Clinical Trial Site
    Gilbert, Arizona 85297, United States
  • Clinical Trial Site
    Phoenix, Arizona 85028, United States
  • Clinical Trial Site
    Sun City, Arizona 85351, United States
  • Clinical Trial Site
    Tempe, Arizona 85281, United States
  • Clinical Trial Site
    Tucson, Arizona 85741, United States
  • Clinical Trial Site
    Beverly Hills, California 90211, United States
  • Clinical Trial Site
    Covina, California 91723, United States
  • Clinical Trial Site
    Encinitas, California 92024, United States
  • Clinical Trial Site
    Garden Grove, California 92844, United States
  • Clinical Trial Site
    Huntington Beach, California 92647, United States
  • Clinical Trial Site
    Los Angeles, California 90022, United States
  • Clinical Trial Site
    Los Angeles, California 90057, United States
  • Clinical Trial Site
    Northridge, California 91324, United States
  • Clinical Trial Site
    Northridge, California 91325, United States
  • Clinical Trial Site
    Pasadena, California 91105, United States
  • Clinical Trial Site
    San Diego, California 92108, United States
  • Clinical Trial Site
    San Diego, California 92111, United States
  • Clinical Trial Site
    San Dimas, California 91773, United States
  • Clinical Trial Site
    Simi Valley, California 93065, United States
  • Clinical Trial Site
    Vacaville, California 95687, United States
  • Clinical Trial Site
    Van Nuys, California 91405, United States
  • Clinical Trial Site
    West Hills, California 91307, United States
  • Clinical Trial Site
    Colorado Springs, Colorado 80918, United States
  • Clinical Trial Site
    Denver, Colorado 80210, United States
  • Clinical Trial Site
    Denver, Colorado 80230, United States
  • Clinical Trial Site
    Hartford, Connecticut 06112, United States
  • Clinical Trial Site
    Middlebury, Connecticut 06762, United States
  • Clinical Trial Site
    Waterbury, Connecticut 06708, United States
  • Clinical Trial Site
    Washington D.C., District of Columbia 20009, United States
  • Clinical Trial Site
    Clearwater, Florida 33756, United States
  • Clinical Trial Site
    Coral Gables, Florida 33134, United States
  • Clinical Trial Site
    Daytona Beach, Florida 32117, United States
  • Clinical Trial Site
    Fort Myers, Florida 33912, United States
  • Clinical Trial Site
    Hollywood, Florida 33021, United States
  • Clinical Trial Site
    Jacksonville, Florida 32204, United States
  • Clinical Trial Site
    Jacksonville, Florida 32209, United States
  • Clinical Trial Site
    Jacksonville, Florida 32256, United States
  • Clinical Trial Site
    Jensen Beach, Florida 34957, United States
  • Clinical Trial Site
    Lake City, Florida 32055, United States
  • Clinical Trial Site
    Miami, Florida 33126, United States
  • Clinical Trial Site
    Miami, Florida 33135, United States
  • Clinical Trial Site
    Miami, Florida 33137, United States
  • Clinical Trial Site
    Miami, Florida 33144, United States
  • Clinical Trial Site
    Miami, Florida 33155, United States
  • Clinical Trial Site
    Miami, Florida 33176, United States
  • Clinical Trial Site
    Miramar, Florida 33027, United States
  • Clinical Trial Site
    Orlando, Florida 32801, United States
  • Clinical Trial Site
    The Villages, Florida 32162, United States
  • Clinical Trial Site
    Winter Haven, Florida 33880, United States
  • Clinical Trial Site
    Acworth, Georgia 30101, United States
  • Clinical Trial Site
    Atlanta, Georgia 30322, United States
  • Clinical Trial Site
    Columbus, Georgia 31904, United States
  • Clinical Trial Site
    Douglasville, Georgia 30134, United States
  • Clinical Trial Site
    Gainesville, Georgia 30501, United States
  • Clinical Trial Site
    Savannah, Georgia 31406, United States
  • Clinical Trial Site
    Thomasville, Georgia 31792, United States
  • Clinical Trial Site
    Boise, Idaho 83706, United States
  • Clinical Trial Site
    Chicago, Illinois 60602, United States
  • Clinical Trial Site
    Elkhart, Indiana 46514, United States
  • Clinical Trial Site
    Evansville, Indiana 47714, United States
  • Clinical Trial Site
    Richmond, Indiana 47374, United States
  • Clinical Trial Site
    El Dorado, Kansas 67042, United States
  • Clinical Trial Site
    Newton, Kansas 67114, United States
  • Clinical Trial Site
    Wichita, Kansas 67207, United States
  • Clinical Trial Site
    Owensboro, Kentucky 42303, United States
  • Clinical Trial Site
    Monroe, Louisiana 71201, United States
  • Clinical Trial Site
    New Orleans, Louisiana 70119, United States
  • Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • Clinical Trial Site
    West Springfield, Massachusetts 01089, United States
  • Clinical Trial Site
    Flint, Michigan 48504, United States
  • Clinical Trial Site
    Shelby, Michigan 48315, United States
  • Clinical Trial Site
    Ypsilanti, Michigan 48197, United States
  • Clinical Trial Site
    Minneapolis, Minnesota 55404, United States
  • Clinical Trial Site
    Richfield, Minnesota 55423, United States
  • Clinical Trial Site
    Columbus, Mississippi 39705, United States
  • Clinical Trial Site
    Tupelo, Mississippi 38801, United States
  • Clinical Trial Site
    Creve Coeur, Missouri 63141, United States
  • Clinical Trial Site
    Kalispell, Montana 59901, United States
  • Clinical Trial Site
    Lincoln, Nebraska 68510, United States
  • Clinical Trial Site
    Omaha, Nebraska 68114, United States
  • Clinical Trial Site
    Las Vegas, Nevada 89121, United States
  • Clinical Trial Site
    Portsmouth, New Hampshire 03801, United States
  • Clinical Trial Site
    Berlin, New Jersey 08009, United States
  • Clinical Trial Site
    Albuquerque, New Mexico 87109, United States
  • Clinical Trial Site
    New York, New York 10017, United States
  • Clinical Trial Site
    Charlotte, North Carolina 28287, United States
  • Clinical Trial Site
    Durham, North Carolina 27704, United States
  • Clinical Trial Site
    Durham, North Carolina 27713, United States
  • Clinical Trial Site
    Greensboro, North Carolina 27401, United States
  • Clinical Trial Site
    Greenville, North Carolina 27834, United States
  • Clinical Trial Site
    Monroe, North Carolina 28112, United States
  • Clinical Trial Site
    Raleigh, North Carolina 27609, United States
  • Clinical Trial Site
    Wilmington, North Carolina 28403, United States
  • Clinical Trial Site
    Winston-Salem, North Carolina 27103, United States

Showing the first 100 of 195 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2025, 15 months.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 15 months is close to that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 22, 2024
StartActual
Feb 29, 2024
Primary completionActual
Jun 19, 2025
CompletionActual
Dec 1, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06272487
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Feb 29, 2024
Primary completion
Jun 19, 2025
Completion
Dec 1, 2025
Last update
Mar 2, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilebesiran

Start the discussion